Literature DB >> 26098208

The many faces of type I interferon in systemic lupus erythematosus.

Claudia Mauri, Madhvi Menon.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with a broad spectrum of clinical presentations involving multiple organ systems. An abnormal response to self-antigens is thought to drive the development of SLE; however, the factors that underlie this dysfunction are not clear. In this issue of the JCI, Li and colleagues present compelling evidence to show that type I interferons (IFNs) produced by plasmacytoid dendritic cells inhibit the clearance of apoptotic cells (ACs) by marginal zone macrophages. Specifically, type I IFNs increase the translocation of marginal zone (MZ) B cells to the follicular region of the spleen, thereby disrupting interactions between these B cells and MZ macrophages (MZMs), which in turn disrupts megakaryoblastic leukemia 1-mediated (MKL1-mediated) mechanosensing and inhibits AC phagocytosis by MZMs. The results of this study provide important insight into factors that inhibit AC clearance and promote the development of SLE.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26098208      PMCID: PMC4563695          DOI: 10.1172/JCI82574

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

Review 1.  Cytokine regulation of B-cell migratory behavior favors formation of germinal centers in autoimmune disease.

Authors:  John D Mountz; John H Wang; Shutao Xie; Hui-Chen Hsu
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

Review 2.  The role of type I interferon production by dendritic cells in host defense.

Authors:  P Fitzgerald-Bocarsly; D Feng
Journal:  Biochimie       Date:  2007-05-08       Impact factor: 4.079

Review 3.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

4.  Marginal zone macrophages suppress innate and adaptive immunity to apoptotic cells in the spleen.

Authors:  Tracy L McGaha; Yunying Chen; Buvana Ravishankar; Nico van Rooijen; Mikael C I Karlsson
Journal:  Blood       Date:  2011-03-28       Impact factor: 22.113

Review 5.  Monocyte and macrophage abnormalities in systemic lupus erythematosus.

Authors:  Yi Li; Pui Y Lee; Westley H Reeves
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-07-31       Impact factor: 4.291

6.  Type I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in mice.

Authors:  John H Wang; Qi Wu; Pingar Yang; Hao Li; Jun Li; John D Mountz; Hui-Chen Hsu
Journal:  Arthritis Rheum       Date:  2011-04

7.  Delta-like 1 is essential for the maintenance of marginal zone B cells in normal mice but not in autoimmune mice.

Authors:  Yuko Moriyama; Chiyoko Sekine; Akemi Koyanagi; Noriko Koyama; Hideko Ogata; Shigeru Chiba; Sachiko Hirose; Ko Okumura; Hideo Yagita
Journal:  Int Immunol       Date:  2008-04-01       Impact factor: 4.823

Review 8.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29

9.  Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL.

Authors:  Maria K Vartiainen; Sebastian Guettler; Banafshe Larijani; Richard Treisman
Journal:  Science       Date:  2007-06-22       Impact factor: 47.728

Review 10.  Fifty years of anti-ds DNA antibodies: are we approaching journey's end?

Authors:  D A Isenberg; J J Manson; M R Ehrenstein; A Rahman
Journal:  Rheumatology (Oxford)       Date:  2007-05-11       Impact factor: 7.580

View more
  3 in total

Review 1.  Effects of type I interferons in malaria.

Authors:  Ismail Sebina; Ashraful Haque
Journal:  Immunology       Date:  2018-07-05       Impact factor: 7.397

2.  Association Between a History of Nontyphoidal Salmonella and the Risk of Systemic Lupus Erythematosus: A Population-Based, Case-Control Study.

Authors:  Ting-Yu Tu; Chiu-Yu Yeh; Yao-Min Hung; Renin Chang; Hsin-Hua Chen; James Cheng-Chung Wei
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

Review 3.  JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.

Authors:  Meredyth G Ll Wilkinson; Claire T Deakin; Charalampia Papadopoulou; Despina Eleftheriou; Lucy R Wedderburn
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-25       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.